HAS-BLED Bleeding Risk Score
Adds the seven HAS-BLED items, from hypertension and labile INR to age over 65 and drug or alcohol use, and rates bleeding risk under oral anticoagulation.
HAS-BLED
—
HAS-BLED: bleeding risk on oral anticoagulation
The HAS-BLED estimates the annual risk of major bleeding in patients on oral anticoagulation, most often in the setting of atrial fibrillation. Each item scores 1 point unless noted otherwise: Hypertension uncontrolled (SBP >160), Abnormal renal function (1) and/or hepatic function (1), Stroke prior, Bleeding history or predisposition, Labile INR (TTR <60%), Elderly >65 years, Drugs (antiplatelets/NSAIDs) (1) and/or alcohol abuse (1). The total runs from 0–9. Reading it: 0–2 low/moderate risk, ≥3 high risk, which calls for closer monitoring but does not contraindicate anticoagulation. Example: a 70-year-old hypertensive (uncontrolled) patient on aspirin scores 1+1+1 = 3 → high risk, so step up the follow-up.
Clinical context
It was validated in 2010 (Pisters et al.) and has since been adopted by the ESC and the Brazilian Society of Cardiology. You use it alongside CHA2DS2-VASc, never in place of it. Where the score really earns its keep is in flagging reversible factors: getting blood pressure under control, cutting alcohol, revisiting concomitant NSAIDs and antiplatelets, tightening INR control. It fits patients on warfarin or DOACs, AF clinics, post-thromboembolism follow-up, and the call on whether to combine antiplatelet with anticoagulant therapy.
FAQ
Does HAS-BLED ≥3 contraindicate anticoagulation? No. It tells you bleeding risk is elevated, so reversible factors need attention and monitoring should be tighter. It is not a reason to withhold anticoagulation that CHA2DS2-VASc indicates.
Does the labile INR criterion apply to DOACs? No. It applies only to warfarin (TTR <60% over the last 6 months). With DOACs, leave this item out.
What counts as renal/hepatic abnormality? On the renal side: creatinine >2.26 mg/dL, dialysis, or transplant. On the hepatic side: cirrhosis, or bilirubin >2× normal together with AST/ALT >3× normal.
How often should I reassess? At least once a year, and again after any clinically relevant change such as a new medication, declining kidney function, or a hospitalization.
Related Tools
Modigliani M² Measure
Computes Modigliani's M² measure (also M-squared or RAP), which translates the Sharpe ratio back into percentage points of return. The idea is plain: scale the portfolio to the market's volatility and ask what it would have returned under those conditions, M² = Rf + (Rp − Rf)·(σmarket/σportfolio). Unlike the Sharpe ratio, a bare number, M² compares directly against the benchmark's return. Above the market return, the portfolio beat the benchmark on a risk-adjusted basis. Enter the portfolio return and volatility, the risk-free rate and the market volatility.
CDS Par Spread (Reduced-Form)
Computes the par (breakeven) spread of a Credit Default Swap in the reduced-form model with a constant hazard rate, setting the present value of the protection leg — which pays 1−R on default — equal to that of the premium leg. It shows the credit-triangle relationship s ≈ (1−R)·λ in practice. Enter the hazard rate, recovery rate, maturity, payment frequency and risk-free rate; the result is in basis points.
Effective Dose
Compute the effective dose, E = H·wT, multiplying the equivalent dose in an organ (H, in mSv) by the tissue weighting factor (wT) reflecting the tissue's radiosensitivity. While the equivalent dose accounts for the radiation type, the effective dose weights the risk by the irradiated organ (gonads and marrow are more sensitive than skin or bone). It is the quantity used in occupational dose limits. Enter the equivalent dose and the tissue weighting factor.
Spread Duration (Numerical)
Computes the spread duration of a bond by finite differences, repricing the instrument for an up and a down move in the credit spread: (V− − V+)/(2·V0·Δs). While duration measures sensitivity to changes in the risk-free rate, spread duration isolates sensitivity to the credit spread, the premium the market charges for issuer risk. It's essential for managing credit portfolios, where spread risk often dominates. Enter the base price, the prices with higher and lower spread and the spread change used.
Volatility Drag (Variance Drag)
Computes volatility drag: the loss of the compound (geometric) return relative to the average (arithmetic) return, approximately volatility squared divided by two. It's the reason a portfolio that does +50% and then −50% doesn't return to the start: volatility erodes compound growth. The more volatile the asset, the larger the drag, even with the same average return. Enter the arithmetic mean return and the volatility.
Pain Index
Computes the pain index of a series: the average depth underwater, that is, the mean of all point-by-point drawdowns across the history. While the maximum drawdown looks only at the worst moment, the pain index measures the average suffering — how long and how deep the portfolio stayed below its peaks. It's a cousin of the ulcer index, which uses the root mean square instead of the simple average. Enter the series of values separated by commas.
The results provided by this tool are for general informational and educational purposes only and do not constitute professional, financial, medical, legal, tax or accounting advice. Always confirm important decisions with a qualified professional and official sources.